Commentary|Videos|November 19, 2026

Recognizing Menin Inhibitor Differentiation Syndrome as an AML Class Effect

Amir T. Fathi, MD, outlines what menin inhibitors must show for frontline approval and how to manage differentiation syndrome.

Menin inhibitors are being evaluated in phase 3 frontline acute myeloid leukemia (AML) trials, including KOMET-017 (NCT07007312), which is testing ziftomenib (Komzifti) with either intensive chemotherapy or venetoclax (Venclexta) and azacitidine (Vidaza), and EVOLVE-2 (NCT06652438), which is testing revumenib (Revuforj) with venetoclax and azacitidine in patients ineligible for intensive chemotherapy.1,2 Differentiation syndrome, which can arise as these agents drive differentiation of leukemic blasts, is a recognized toxicity of the class that clinicians must monitor for.

Amir T. Fathi, MD, director of the leukemia program at the Mass General Brigham Cancer Institute and professor of medicine at Harvard Medical School, spoke with CancerNetwork® at the 44th Annual Chemotherapy Foundation Symposium (CFS®), hosted by Physicians’ Education Resource®, LLC, following his presentation, “Challenging the Dogma in Frontline AML Management.” He discussed what must be shown before menin inhibitors move into standard frontline care and how he thinks about differentiation syndrome.

Transcript:

CancerNetwork: Menin inhibitors are in phase 3 frontline trials combined with venetoclax/azacitidine or with intensive chemotherapy. What has to be shown before they move into standard frontline care, and how do you think about the added toxicity, such as differentiation syndrome and QTc effects?

Fathi: That’s a broad question, so I’ll tackle the first [part] first. In general, the goal of the various phase 3 trials studying multiple menin inhibitors in combination with standard therapies is registration, to have approval, and each of these has a different primary end point. Some are similar, but each study is different. If the studies are positive and meet their primary end points, the companies will submit their data to regulatory bodies in Europe, the United States, and perhaps elsewhere…Hopefully, if the data are strong enough, there would be approval of one or multiple menin inhibitors in combination. At least that’s the hope of the field.

As far as differentiation syndrome, it is a class effect that arises from the mechanism of action of these drugs. When these drugs trigger differentiation of abnormal myeloid blasts, hopefully into normal cells, that can trigger differentiation syndrome, which is a pleomorphic, nonspecific inflammatory cascade that can be challenging and sometimes deadly. It’s uncommon, but it can be. It is important to recognize and important to monitor. Generally, though not always, when it does occur, it occurs within the first week or 2 following initiation of treatment with menin inhibitors.

References

  1. Studies to assess ziftomenib in combination with Ven+Aza or 7+3 in patients with untreated NPM1-m or KMT2A-r AML. ClinicalTrials.gov. Updated November 12, 2026. Accessed November 17, 2026. https://tinyurl.com/y7zewfet
  2. Revumenib in combination with azacitidine + venetoclax in patients NPM1-mutated or KMT2A-rearranged AML. ClinicalTrials.gov. Updated September 2, 2026. Accessed November 17, 2026. https://tinyurl.com/5echezv3

Related to this article